Topical 1.5% ruxolitinib cream for facial refractory segmental vitiligo: a retrospective single-center case series
Published: 11 August 2025| Version 1 | DOI: 10.17632/mnr6vbbjyp.1
Contributors:
Hequn Huang, Dawei Duan, He Huang, Xianfa Tang, Caihong Zhu, Yaohua Zhang, Min Li, Yujun Sheng, Leihong Xiang, Yong Cui, Youwen Zhou, Xuejun Zhang, bo zhangDescription
Segmental vitiligo (SV) is characterized by unilateral skin depigmentation, often unresponsive to standard treatments. This study reports on 40 patients with refractory facial SV treated with 1.5% ruxolitinib cream, showing a 45% VASI75 improvement rate at 24 weeks. Key findings include: • Higher VASI75 rates in progressive-stage patients • Comparable efficacy to traditional therapies but lower than non-segmental vitiligo results • No serious adverse reactions observed.
Files
Categories
Ruxolitinib, Vitiligo